Bethphagen Inc.

Gwangju Institute of Science and Technology

Seoul National University

Daewoo Electronics Co., Ltd.

Olives Biotherapeutics Inc.

Elancer Inc.

Woo Jin Park

Jae Gyun Oh

Roger J Hajjar

Tae Hwan Kwak

Dong Kwon Yang

Aeri Yoon

Seung Won Baek

Hye-eun Han

Taek Beom Yoo

Hae Seok Jeong

Byoung Hyun Choi

Soo Min Hyun

Yoon Jin Lee

Min-Ah Lee

Pyoung Oh Yoon

Min Ho Lee

Seung Pil Jang

Hae Hyun Lee

A pharmaceutical composition containing a CCN5 or a fragment thereof, a nucleic acid encoding the CCN5, a vector containing the nucleic acid, or a recombinant cell containing the nucleic acid or the vector, as an active ingredient and its use in preventing or treating retinal diseases are disclosed. The CCN5 prevents fibrotic changes, caused by TGF-β, EEF, or anti-VEGF drugs, in retinal pigment epithelial cells. In addition, CCN5 recuperates the morphological or functional damage, caused by fibrotic changes, of retinal pigment epithelial cells to the level of normal cells. Therefore, the composition containing CCN5 as an active ingredient can be advantageously utilized for preventing or treating retinal diseases.

Pharmaceutical composition comprising CCN5 as active ingredient, for preventing or treating retinal diseases

The present invention relates to a pharmaceutical composition for prevention and treatment of heart failure. Specifically, the present invention relates to a gene construct comprising a polynucleotide coding for SERCA2a protein or a fragment thereof and a polynucleotide coding for CCN5 protein or a fragment thereof, and a pharmaceutical composition comprising the same construct as an effective ingredient for preventing or treating heart failure. A pharmaceutical composition for prevention and treatment of heart failure according to the present invention is used in a method for co-expression of SERCA2a protein and CCN5 protein. Designed to exert a synergistic therapeutic effect through SERCA2a protein's function of preventing the loss of cardiomyocytes and increasing the activity of cardiomyocytes and CCN5 protein's function of suppressing the fibrosis of heart cells and tissues, the pharmaceutical composition can be useful for preventing or treating heart failure, which is a complex disorder induced by various etiological factors.

Pharmaceutical composition for prevention or treatment of heart failure

A pharmaceutical composition suitable for preventing or treating cardiac arrhythmia is disclosed. The pharmaceutical composition contains, as an active ingredient, a CCN5 protein or a nucleotide encoding the CCN5 protein. The pharmaceutical composition inhibits the pathological activity of CaMKII, which induces cardiac electrical abnormalities that is the main cause of atrial arrhythmia and ventricular arrhythmia, so as to restore the electrical functions, and inhibits the activity of myofibroblasts causing structural abnormalities. Therefore, the pharmaceutical composition can be effectively used in the prevention or treatment of cardiac arrhythmia.

Pharmaceutical composition for preventing or treating cardiac arrhythmia

The present invention relates to a composition comprising a protein phosphatase 1 inhibitory peptide for treating vascular diseases. The composition of the present invention inhibits protein phosphatase 1 (PP1)-mediated dephosphorylation to suppress abnormal proliferation of vascular smooth muscle cells (VSMCs), and activates eNOS of vascular endothelial cells (VECs) to induce the recovery from dysfunction, and thus can be favorably used in the treatment of vascular diseases including pulmonary hypertension.

Composition comprising protein phosphatase 1 inhibitory peptide for treating vascular diseases

The present invention relates to decoy peptide or polypeptide consisting of a peptide sequence represented by the following Formula I: X-Ala-X&#x2014;X-Ile-Glu-X(I). It is noteworthy that the decoy peptide or polypeptide of the present invention significantly elevates phosphorylation levels of PLB by inhibiting PP1-mediated dephosphorylation. In addition, the decoy peptide or polypeptide provides cardio-protective effects by restoring of SERCA2a activity and inotropic effect of enhancing myocardial contractility. The present invention will contribute greatly to the prevention or treatment of diseases associated with PLB.

Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban

A dry eye syndrome alert system through posture and work detection, includes: a data collecting unit configured to detect a posture of a user to collect posture data of the user and preprocess the posture data; an eye blink frequency calculating unit configured to identify a posture change of the user on the basis of the posture data, calculate a motion variability on the basis of the posture change, and estimate an eye blink frequency of the user on the basis of the motion variability; and a diagnosis and alert output unit configured to store data regarding the estimated eye blink frequency, compare the estimated eye blink frequency with a preset reference value, and output an alert to the user when the estimated eye blink frequency is less than or equal to the preset reference value.

Dry eye syndrome alert system through posture and work detection

The present invention relates to decoy peptide or polypeptide consisting of a peptide sequence represented by the following Formula I: X-Ala-X-X-Ile-Glu-X(I). It is noteworthy that the decoy peptide or polypeptide of the present invention significantly elevates phosphorylation levels of PLB by inhibiting PP1-mediated dephosphorylation. In addition, the decoy peptide or polypeptide provides cardio-protective effects by restoring of SERCA2a activity and inotropic effect of enhancing myocardial contractility. The present invention will contribute greatly to the prevention or treatment of diseases associated with PLB.

Decoy peptides inhibiting protein phosphatase 1-medicated dephosphorylation of phospholamban

The present invention relates to a pharmaceutical composition for preventing or treating a heart failure and a method for screening a therapeutic agent for preventing or treating a heart failure. The pharmaceutical composition of the present disclosure comprises the CCN5 or CCN2&#x394;CT protein, or a genetic carrier comprising a nucleotide sequence encoding the CCN5 or the CCN2&#x394;CT protein, exhibiting dramatic prevention or treatment efficacies on a heart failure even without surgical treatments accompanied with transplanting a donor heart.

Pharmaceutical composition comprising CCN5 for reducing cardiac fibrosis in a subject in need thereof

The present invention relates to a pharmaceutical composition for preventing or treating an amyloid &#x3b2;-caused disease, which comprises as an active ingredient a NIa (nuclear inclusion a) protease or a gene carrier containing a nucleotide sequence encoding the NIa protease. The pharmaceutical composition of this invention is very effective to treat a variety of diseases or disorders, inter alia, Alzheimer's disease.

Amyloid-beta clearance

Provided is a treadmill-related technology. That is, the treadmill device and the operating method of the same is configured to detect a user who is taking exercise in real time, take pictures of the detected user's looks, and insert user image data as the results of data analysis, which are obtained from the taken pictures, into a virtual 3D object moving image which indicates the selected exercise course background, so as to project a 3D user image in which the user's behavior patterns are engaged with a virtual 3D object moving image. Therefore, since the treadmill device is used to allow a user to see his own looks taking exercise in real time, it is possible to prevent the user from feeling boring during exercise, and it is easy to continuously check the user's own physical status or conditions. Also, since a user may actively employ exercise course backgrounds which are freely changed during exercise by the user's choices, the best information on the physical rhythm and exercise conditions may be offered to the user, thereby improving the user's satisfaction and buying power, which leads to an expected increase in the sales.

Treadmill system and operating method of the same

A disc player performs disc loading and ejecting while closing and opening the player lid. The disc player includes a housing having a first guide groove longitudinally formed on an inner side thereof, a deck including a turntable, a moving plate mounted over deck to horizontally move in frontward and rearward directions, a disc tray engaged with the moving plate and for loading and ejecting a disc onto and out of the turntable while vertically moving down and up in response to rearward and frontward movements of the moving plate, a lid engaged with the housing to pivotally close and open, and movement mechanism for controlling the frontward and rearward movements of the moving plate when the lid closes and opens. A simple structure and miniaturization of a disc player can be accomplished since disc loading and ejecting is performed without using a motor and gears.

Growing community of inventors

Seoul, South Korea

Woo Jin Park